NL-GHK-Cu in lung diseases

NL-GHK-Cu peptide therapy during the most common lung diseases and injuries. The protective role of the peptide in maintaining a properly functioning respiratory system.

Abstract: Almost half of the processes occurring in cells cannot take place without oxygen. Unfortunately, the body is unable to store it. As a result, the respiratory system must constantly supply cells with this life-giving gas, which is why maintaining a healthy and properly functioning respiratory system is so important. The NL-GHK-Cu peptide, being a safe and non-toxic peptide, demonstrates the ability to activate numerous pathways that enable therapy aimed at alleviating the symptoms of existing respiratory system diseases, particularly those of the lungs. Additionally, NL-GHK-Cu peptide therapy allows for the preservation of a healthy and properly functioning respiratory system and all of its constituent elements.

Keywords: NL-GHK-Cu; respiratory system; lungs; lung diseases; bronchitis; pneumonia; asthma; tuberculosis; COPD; therapy; respiratory failure; lung injury; pulmonary fibrosis; protection; gas exchange

Introduction

It is well known that NL-GHK-Cu, being a naturally occurring peptide, exhibits a safe, non-toxic and broad spectrum of action. It is released in the body during injury, which is why therapy using it can be successively applied both in protecting the functioning of the respiratory system and in supportive therapy for the regeneration of its elements, particularly the lungs, as the majority of commonly occurring diseases within this system affect them.

STRUCTURE OF THE RESPIRATORY SYSTEM

The respiratory system consists of the upper and lower airways and the gas exchange organ, namely the lungs. The upper airways include the nasal cavity and the pharynx. The lower airways include the larynx, trachea and bronchi. The proper and primary organ of respiration is the lungs. Furthermore, the respiratory system includes respiratory muscles such as the diaphragm, the external and internal intercostal muscles, and accessory respiratory muscles.

FUNCTIONS OF THE RESPIRATORY SYSTEM

The respiratory system ensures the efficient intake and transport of respiratory gases, namely oxygen and carbon dioxide, as well as gas exchange consisting of the uptake of oxygen from the lungs into the blood and the expulsion of carbon dioxide from the blood into the lungs, and subsequently further out of the body through the airways. Each element of the respiratory system fulfills its specific function: in the case of the nasal cavity, this is the cleaning, warming and humidifying of inhaled air; in the case of the larynx, it is enabling the production of sound; in the case of the trachea, it is the transport of air to the bronchi; and in the case of the main bronchi, it is enabling air to reach the alveoli. Focusing on the important process of gas exchange, the bronchi divide into increasingly smaller branches ending in alveoli. From the alveoli, oxygen passes into the blood. Carried by the blood, it travels throughout the entire body and reaches all of its cells. From each cell, carbon dioxide passes into the blood. It is transported to the lungs, where it passes from the blood into the interior of the alveoli. It is then removed from them along with exhaled air. Both processes, i.e. the uptake of oxygen into the blood and the removal of carbon dioxide from it, occur simultaneously.

THE LUNGS

The lungs are shaped like large, spongy and elastic sacs. They are gas exchange organs located in the chest cavity. On the outside they are protected by a thin double membrane called the pleura, which is filled with a small amount of fluid. This prevents damage to the lungs from friction against the ribs and other chest bones during respiratory movements. Inside the lungs, the bronchi branch out in a tree-like manner, forming a system of increasingly smaller tubes called bronchioles. At their ends are the alveoli. The alveoli are surrounded by a dense network of capillaries. Between them and the air coming from the alveolus, gas exchange takes place by diffusion. The penetration of oxygen into the blood and carbon dioxide from the blood into the alveolus occurs very quickly and efficiently thanks to three fundamental aspects:

1. The walls of the alveolus and the capillary blood vessels are composed of a thin single-layer flat epithelium;
2. The network of capillaries covering the alveoli is very dense;
3. The alveoli form a very large gas exchange surface. LUNG DISEASES

The proper functioning of the respiratory system is essential for maintaining the health and good condition of the entire body. Unfortunately, year after year the number of people affected by lung diseases is growing, driven by various causative factors including environmental, genetic, and inappropriate lifestyle factors. Among the most commonly diagnosed lung diseases, aside from cancer, are sarcoidosis, cystic fibrosis, and chronic obstructive pulmonary disease (COPD).

GHK-CU IN LUNG DISEASES

The NL-GHK-Cu peptide, being a safe and non-toxic peptide, demonstrates the ability to activate numerous pathways that enable therapy aimed at alleviating the symptoms of existing respiratory system diseases, particularly those of the lungs. Additionally, NL-GHK-Cu peptide therapy allows for the preservation of a healthy and properly functioning respiratory system and all of its constituent elements.

GHK-CU THERAPY IN THE CASE OF ACUTE LUNG INJURY AND RESPIRATORY FAILURE

Acute lung injury (ALI), together with its most severe form, acute respiratory distress syndrome (ARDS), is a disorder of acute inflammation and tissue damage characterized by loss of alveolar-capillary membrane integrity, excessive transepithelial neutrophil migration and the release of pro-inflammatory and cytotoxic mediators, leading to lung damage, which may result in, among other things, respiratory failure. NL-GHK-Cu peptide therapy: Studies have demonstrated that NL-GHK-Cu peptide therapy reduced the production of reactive oxygen species (ROS) and increased superoxide dismutase (SOD) activity while simultaneously reducing the production of TNF-α and IL-6 by suppressing NF-κB p65 and p38 MAPK signaling, whereby the peptide attenuated histological lung changes induced by injury and suppressed the infiltration of inflammatory cells into the lung parenchyma, resulting in the alleviation of lung injury and the elimination of inflammation occurring within it. Additionally, the NL-GHK-Cu peptide supported regenerative processes following inflammation.

GHK-CU THERAPY IN THE CASE OF PULMONARY FIBROSIS

Pulmonary fibrosis is a condition that, as a consequence of lifestyle, typically affects older individuals, although symptoms of this condition can also be identified in children. There are many predisposing factors for the development of pulmonary fibrosis. The most common causes include, among others, cigarette smoking, exposure to harmful dusts, environmental factors and certain medications.

NL-GHK-Cu peptide therapy: The GHK peptide alone, without the copper component, has found application in degenerative neuropathies and disorders by suppressing the peroxidation process. In combination, the NL-GHK-Cu complex, thanks to the attached metal ion, activates superoxide dismutase (SOD), which is dependent on Cu and Zn, promoting endogenous antioxidant activity. The NL-GHK-Cu complex reduces oxidative damage by inhibiting inflammation and reducing the release of ferritin iron in damaged tissues. Additionally, NL-GHK-Cu reduces the production of reactive oxygen species (ROS), increases SOD activity, while simultaneously reducing the release of pro-inflammatory cytokines in acute lung injury induced by fibrosis.

GHK-CU THERAPY IN THE CASE OF COPD

Chronic obstructive pulmonary disease (COPD) is a respiratory system condition whose causes are most commonly environmental in nature. Patients suffering from COPD experience symptoms resulting from disturbed airflow through the lungs. The disease itself carries a poor prognosis, which is why its rapid diagnosis is important, and consequently the commencement of appropriate therapeutic and supportive treatment.

NL-GHK-Cu peptide therapy: It has been demonstrated that the NL-GHK-Cu complex supports the remodeling and restructuring of connective tissue and modulates the expression of many genes, including the regulation of genes in the TGF-β pathway. In this way, NL-GHK-Cu demonstrates the ability to reverse the expression of key genes contained in the COPD gene signature, i.e. chronic obstructive pulmonary disease. The expression of 127 genes was altered in patients with COPD. More severe emphysema symptoms were correlated with the degree of change in gene expression. Genes whose expression was associated with inflammation were upregulated, while genes involved in tissue remodeling and repair were significantly downregulated. NL-GHK-Cu is a peptide that can reverse changes in gene expression associated with emphysema destruction, such as reduced activity of genes involved in the TGF-β pathway, in such a way that under the influence of NL-GHK-Cu it was able to reverse the pattern of gene expression to its opposite, activating the TGF-β pathway. NL-GHK-Cu may additionally exert a beneficial effect on connective tissue. Lung fibroblasts derived from COPD patients, which had impaired ability to contract and restructure collagen, were supported with NL-GHK-Cu or TGF-β therapy. Both molecules restored fibroblast function and elevated the expression of integrin beta 1.

THE PROTECTIVE ROLE OF NL-GHK-CU

The use of the NL-GHK-Cu peptide protects lung tissue from induced acute lung injury (ALI) and inhibits the infiltration of inflammatory cells into the lungs. The NL-GHK-Cu peptide also increased superoxide dismutase (SOD) activity while simultaneously reducing the production of TNF-1 and IL-6 by blocking the activation of NFκB p65 and p38 MAPK (mitogen-activated protein kinase). Mitogen-activated protein kinases are kinase enzymes that play a key role in cellular signaling. P38 MAPK pathways enable cells to respond to a wide range of external stressors and influence skin differentiation, apoptosis, motility and gene expression, through which it can be demonstrated that NL-GHK-Cu peptide therapy has a protective effect on the respiratory system in the human body.

REFERENCES

1. Park JR, Lee H, Kim SI, Yang SR. The tri-peptide GHK-Cu complex ameliorates lipopolysaccharide-induced acute lung injury in mice. Oncotarget. 2016;7(36):58405-58417. doi:10.18632/oncotarget.
2. W Ma, M Li, H Ma, W Li, L Liu, Y Yin, X Zhou, G Hou. Protective effects of GHK-Cu in bleomycin-induced pulmonary fibrosis via anti-oxidative stress and anti-inflammation pathways 2019. 10.1016/j.lfs.2019.117139
3. Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018;19(7):1987. Published 2018 Jul 7. doi:10.3390/ijms19071987
4. Michajlik A. Human Anatomy and Physiology. PZWL Publishing House. 2009.